Compare IBEX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | CRMD |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.0M | 590.7M |
| IPO Year | 2017 | 2009 |
| Metric | IBEX | CRMD |
|---|---|---|
| Price | $53.81 | $5.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $46.50 | $13.80 |
| AVG Volume (30 Days) | 132.4K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.63 | ★ 780.00 |
| EPS | ★ 0.99 | 0.57 |
| Revenue | ★ $644,076,000.00 | $311,709,000.00 |
| Revenue This Year | $13.49 | $8.05 |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | $54.55 | ★ $8.89 |
| Revenue Growth | 15.37 | ★ 617.03 |
| 52 Week Low | $25.94 | $4.47 |
| 52 Week High | $57.92 | $13.02 |
| Indicator | IBEX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 39.61 |
| Support Level | $27.98 | N/A |
| Resistance Level | $57.92 | $8.97 |
| Average True Range (ATR) | 2.75 | 0.38 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 74.97 | 58.87 |
IBEX Ltd delivers business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. The company's services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital), and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare, among others, and derives maximum revenue from the United States.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.